Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin Transdrug versus standard treatment for hepatocellular carcinoma
ACTRN12608000082303Phase 3Not yet recruiting
- Sponsor
- Simbec-Orion
- Start
- Apr 2008
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of Livatag in hepatocellular carcinoma (HCC) (2 arms), sponsored by Simbec-Orion. Primary endpoints: Patients free of local progression at 3 months - treatment group and Patients free of local progression at 3 months - control group. Planned start Apr 2008; status: not yet recruiting.
02
Drugs
Livatag
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ACTRN12608000082303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000082303.